Get started
Author

Anne Sumbul

Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial
2018 · Philippe Armand, Andreas Engert, et al. · Journal of Clinical Oncology · 759
PDF
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
2018 · Margaretha G.M. Roemer, Robert A. Redd, et al. · Journal of Clinical Oncology · 365
PDF
Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
2019 · Stephen M. Ansell, Monique C. Minnema, et al. · Journal of Clinical Oncology · 353
Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study
2019 · Radhakrishnan Ramchandren, Eva Domingo-Domènech, et al. · Journal of Clinical Oncology · 252
PDF
Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)
2021 · Hussein A Tawbi, Peter A Forsyth, et al. · Neuro-Oncology · 119
Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma
2020 · Philippe Armand, Ann Janssens, et al. · Blood · 95
PDF
Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma
2016 · John M. Timmerman, Andreas Engert, et al. · Blood · 48
Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study
2017 · Radhakrishnan Ramchandren, Michelle A. Fanale, et al. · Blood · 28
Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) after Treatment with Nivolumab for Relapsed/Refractory Hodgkin Lymphoma
2016 · Philippe Armand, Pier Luigi Zinzani, et al. · Blood · 26
Nivolumab for Relapsed/refractory Classical Hodgkin Lymphoma After Autologous Transplant: Full Results After Extended Follow‐up of the Phase 2 Checkmate 205 Trial
2017 · M. Fanale, A. Engert, et al. · Hematological Oncology · 21
PDF
The tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic with a clinically acceptable safety profile in subjects previously vaccinated with a tetravalent polysaccharide vaccine
2012 · Ghassan Dbaibo, Marie Van der Wielen, et al. · International Journal of Infectious Diseases · 20
PDF
Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study
2018 · Philippe Armand, Andreas Engert, et al. · Blood · 19
ADAPT NXT : Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis
2025 · Ali A. Habib, Kristl G. Claeys, et al. · Annals of Clinical and Translational Neurology · 18
PDF
Safety and Efficacy of Cusatuzumab in Combination with Venetoclax and Azacitidine (CVA) in Patients with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Eligible for Intensive Chemotherapy; An Open-Label, Multicenter, Phase 1b Study
2021 · Gail J. Roboz, Thomas Pabst, et al. · Blood · 14
Nivolumab Plus Doxorubicin, Vinblastine and Dacarbazine for Newly Diagnosed Advanced‐stage Classical Hodgkin Lymphoma: Checkmate 205 Cohort D 2‐year Follow‐up
2019 · S. Ansell, R. Ramchandren, et al. · Hematological Oncology · 12
Chromosome 9p24.1/PD-L1/PD-L2Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade)
2016 · Margaretha G M Roemer, Azra H. Ligon, et al. · Blood · 6
Fixed-cycle and Continuous Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Study Design of ADAPT NXT (P10-11.010)
2024 · Vera Bril, Yessar Hussain, et al. · Neurology · 5
A phase 2 study of a nivolumab (nivo)-containing regimen in patients (pts) with newly diagnosed classical Hodgkin lymphoma (cHL): Study 205 Cohort D.
2016 · Philippe Armand, Margaret Ann Shipp, et al. · Journal of Clinical Oncology · 4
S821 Nivolumab Plus Doxorubicin, Vinblastine and Dacarbazine for Newly Diagnosed Advanced‐stage Classical Hodgkin Lymphoma: 2‐year Extended Follow‐up From Cohort D of the Phase 2 Checkmate 205 Study
2019 · E. Domingo‐Domènech, R. Ramchandren, et al. · HemaSphere · 3
Fixed Cycle and Q2W Dosing of Intravenous Efgartigimod for gMG: Part A of ADAPT NXT
2024 · Jonathan Bosold, Edward Brauer, et al. · Neurology · 2
Allogeneic Hematopoietic Cell Transplantation Outcomes After Nivolumab Monotherapy for Relapsed/Refractory Hodgkin Lymphoma (CA209-039 and CheckMate 205)
2017 · Carmelo Carlo-Stella, Graham P. Collins, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
Checkmate 205 Cohort C: Nivolumab in Patients With Classical Hodgkin Lymphoma After Prior Brentuximab Vedotin and Autologous Hematopoietic Stem Cell Transplantation
2016 · Pier Luigi Zinzani, Andreas Engert, et al. · Kölner Universitäts PublikationsServer (Universität zu Köln) · 1
Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study
2026 · Gail J. Roboz, Thomas Pabst, et al. · Haematologica
PDF
Zyklische und kontinuierliche Dosierung von intravenösem Efgartigimod bei generalisierter Myasthenia gravis: Studiendesign ADAPT NXT
2025 · S Wenninger, V Bril, et al. · Nervenheilkunde
HSR19-107: Nivolumab for Newly Diagnosed Classical Hodgkin Lymphoma: Patient-Reported Outcomes From CheckMate 205 Cohort D
2019 · Radhakrishnan Ramchandren, Stephen M. Ansell, et al. · Journal of the National Comprehensive Cancer Network
Works count: 26
Citation count: 2,172
H-index: 14
I10-index: 15
Year
Topic
Type